The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

Therapeutic targeting of immune checkpoints has garnered significant attention in the area
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival
factor which supports autoreactive B cells and prevents their deletion. BAFF expression is …

The past three decades have witnessed remarkable advances in our ability to target specific
elements of the immune and inflammatory response, fuelled by advances in both …

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients
with systemic lupus erythematosus (SLE). Methods Patients with moderate‐to‐severe SLE …

Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …

Despite recent improvements in the treatment of systemic lupus erythematosus (SLE),
disease activity, comorbidities and drug toxicity significantly contribute to the risk of …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple
organs. A complex interaction of genetics, environment, and hormones leads to immune …

The failure of many new, mostly biologic, drugs to meet their primary end points in double-
blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a …

Abnormalities in B cells play pivotal roles in the pathogenesis of systemic lupus
erythematosus (SLE) and lupus nephritis (LN). Breach in central and peripheral tolerance …